Advances towards the use of gastrointestinal tumor patient-derived organoids as a therapeutic decision-making tool

Simple item page
dc.catalogadorgjm
dc.contributor.authorObreque Castro, Javiera Constanza
dc.contributor.authorVergara Gómez, Luis
dc.contributor.authorVenegas Labra, Nicolás
dc.contributor.authorWeber, Helga
dc.contributor.authorOwen, Gareth Ivor
dc.contributor.authorPérez Moreno, Pablo
dc.contributor.authorLeal, Pamela
dc.contributor.authorRoa Strauch, Juan Carlos Enrique
dc.contributor.authorBizama, Carolina
dc.date.accessioned2023-12-14T15:00:09Z
dc.date.available2023-12-14T15:00:09Z
dc.date.issued2023
dc.date.updated2023-12-03T01:03:31Z
dc.description.abstractIn December 2022 the US Food and Drug Administration (FDA) removed the requirement that drugs in development must undergo animal testing before clinical evaluation, a declaration that now demands the establishment and verification of ex vivo preclinical models that closely represent tumor complexity and that can predict therapeutic response. Fortunately, the emergence of patient-derived organoid (PDOs) culture has enabled the ex vivo mimicking of the pathophysiology of human tumors with the reassembly of tissue-specific features. These features include histopathological variability, molecular expression profiles, genetic and cellular heterogeneity of parental tissue, and furthermore growing evidence suggests the ability to predict patient therapeutic response. Concentrating on the highly lethal and heterogeneous gastrointestinal (GI) tumors, herein we present the state-of-the-art and the current methodology of PDOs. We highlight the potential additions, improvements and testing required to allow the ex vivo of study the tumor microenvironment, as well as offering commentary on the predictive value of clinical response to treatments such as chemotherapy and immunotherapy.
dc.fechaingreso.objetodigital2023-12-27
dc.format.extent27 páginas
dc.fuente.origenBiomed Central
dc.identifier.citationBiological Research. 2023 Dec 02;56(1):63
dc.identifier.doi10.1186/s40659-023-00476-9
dc.identifier.urihttps://doi.org/10.1186/s40659-023-00476-9
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/75493
dc.information.autorucEscuela de Medicina; Obreque Castro, Javiera Constanza; S/I; 1025200
dc.information.autorucEscuela de Medicina; Venegas Labra, Nicolás; S/I; 1079697
dc.information.autorucEscuela de Medicina; Owen, Gareth Ivor; 0000-0003-3807-6054; 1000459
dc.information.autorucEscuela de Medicina; Roa Strauch, Juan Carlos Enrique; 0000-0001-8313-8774; 84743
dc.information.autorucEscuela de Medicina; Bizama, Carolina; 0000-0002-5379-6191; 237745
dc.issue.numero1
dc.language.isoen
dc.nota.accesoContenido completo
dc.revistaBiological Research
dc.rightsacceso abierto
dc.rights.holderThe Author(s)
dc.subjectPatient‑derived organoid
dc.subjectGastrointestinal cancer
dc.subjectPre‑clinical model
dc.subjectDrug response prediction
dc.subjectImmunotherapy
dc.subjectTumor microenvironment
dc.titleAdvances towards the use of gastrointestinal tumor patient-derived organoids as a therapeutic decision-making tool
dc.typeartículo
dc.volumen56
sipa.codpersvinculados1025200
sipa.codpersvinculados1079697
sipa.codpersvinculados1000459
sipa.codpersvinculados84743
sipa.codpersvinculados237745
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
40659_2023_Article_476.pdf
Size:
1.89 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.98 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos de revistas